University of Nottingham School of Medicine

The biggest modern breakthrough for cancer treatment has been antibody therapies. An increasing number of biotechnology companies have antibody – or vaccine-based cancer therapies in development. This course aims to attract students interested in tumour immunology who wish to pursue a career either in industry (biotechnology) or academia.

  • Acquire a specialised knowledge in tumour immunology with particular reference to monoclonal antibody and cancer vaccines
  • Develop the critical and analytical power to evaluate scientific literature
  • Perform a scientific research project
  • Acquire the ability to communicate scientific results orally and in writing
  • Learn about business exploitation of cancer therapy

Entry requirements

Please contact the course provider.

Closing date

Please contact the course provider.